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Background: Mutations in the SLC26A4 gene, which encodes the anion transporter, pendrin, are a major cause of
autosomal recessive non-syndromic hearing loss (NSHL) in some Asian populations. SLC26A4 c.919-2A>G
(IVS7-2A>G) is the most common mutation in East Asian deaf populations. To provide a basis for improving the
clinical diagnosis of deaf patients, we evaluated 80 patients with the SLC26A4 c.919-2A>G monoallelic mutation
from 1065 hearing-impaired subjects and reported the occurrence of a second mutant allele in these patients.
Methods: The occurrence of a second mutant allele in these 80 patients with a single c.919-2A>G mutation was
investigated. Mutation screening was performed by bidirectional sequencing in SLC26A4 exons 2 to 6 and 9 to 21.
Results: We found that 47/80 patients carried another SLC26A4 c.919-2A>G compound mutation. The five most
common mutations were: p.H723R, p.T410M, 15+5G>A (c.1705+5G>A), p.L676Q and p.N392Y. We found a
Chinese-specific SLC26A4 mutation spectrum and an associated SLC26A4 contribution to deafness.
Conclusion: Our study illustrates that mutation analysis of other SLC26A4 exons should be undertaken in deaf
patients with a single heterozygous SLC26A4 mutation. Moreover, a model of compound heterozygosity may
partially explain the disease phenotype.Background
Hearing loss is the most prevalent form of sensory impair-
ment in humans. Approximately 1 in 1,000 children are
born with hearing loss severe enough to require special
education services [1]. Deafness in at least half of all
infants with profound hearing loss can be attributed to
genetic factors; of these, nonsyndromic recessive causes
comprise approximately 75–80% [1]. The gap junction
beta-2 (GJB2) gene, which encodes connexin 26 (a compo-
nent of gap junctions), is the most common cause of sen-
sorineural hearing loss (SNHL). Mutations in the GJB2
gene are responsible for about 50% of recessively-inherited
hearing loss in many populations [2].
The SLC26A4 gene, which encodes pendrin, is the second
leading cause of autosomal recessive deafness characterized* Correspondence: daipu301@vip.sina.com
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reproduction in any medium, provided the orby congenital deafness or progressive pre- or postlingual
hearing impairment [3-6]. The SLC26A4 gene is composed
of 21 exons within 2343-bp cDNA on chromosome 7q22-
q31 [7]. Mutations in the SLC26A4 gene are found in not
only patients with Pendred syndrome (PS; OMIM # 274600),
but also in individuals afflicted with nonsyndromic hearing
loss (NSHL) with enlarged vestibular aqueduct (EVA) at the
DFNB4 locus [5,7-9]. SLC26A4 gene studies have revealed
that pendrin is a transmembrane anion transporter that is
highly expressed in the inner ear and functions as an iodide/
chloride transporter [10]. Pendrin is also a microtubule-
associated structural protein that is likely involved in regula-
tion of endolymphatic fluid pH through the secretion of
HCO3
- ions [11]. SLC26A4 mutations associated with non-
syndromic sensorineural hearing loss with EVA showed par-
tial transport function of pendrin, which may be sufficient to
maintain thyroid function and eliminate goiter [12].
To-date, more than 170 SLC26A4 sequence variations
have been identified (Pendred/BOR HomePage, http://
www.healthcare.uiowa.edu/labs/pendredandbor/slcMuta-
tions.htm), including missense, frame-shift, splice-site,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions cover all 21 exons of the SLC26A4 gene. However,
the c.919-2A>G (IVS7-2A>G) mutation, which may
cause deletion of exons surrounding a splice site, is a
hotspot mutation in the Chinese population [13].
We established a nationwide DNA repository of sam-
ples from deaf probands to pursue a sequential screening
strategy to identify gene mutations for deafness and to
inform etiological diagnoses in China. This strategy
yielded an estimation of the prevalence of SLC26A4
c.919-2A>G in deaf individuals in a large Chinese popula-
tion [14]. Previous work revealed that the frequency of
c.919-2A>G monoallelic mutations was 7.6% in our sam-
ple of the Chinese deaf population [14]. Moreover, only
two other mutations (i.e., c.915insG and c.918+44delACA)
were identified in addition to c.919-2A>G by direct se-
quencing analysis of SLC26A4 exons 7 and 8 with intron
7 in 1552 SNHL patients in China. Therefore, c.919-2A>G
accounts for 99% of all mutant alleles in SLC26A4 exons 7
and 8 (278/280) [15].
The presence of two SLC26A4 mutations (i.e., homo-
zygous or compound heterozygous; subsequently re-
ferred to as biallelic) is associated with NSHL and EVA
[6,16,17]. Biallelic mutations in the SLC26A4 gene are a
common cause of inner ear malformations and defective
endolymph homeostasis [18,19]. Recently, two studies
carried out in PS and non-PS (EVA–Mondini) patients
were published. In the first [20], the authors reported
that PS patients were more likely to have two mutations,
as opposed to one or none in non-PS (EVA–Mondini)
patients. In the second study [17], patients with biallelic
mutations had more severe deafness, an earlier age of
onset, and a more fluctuating course of hearing levels
than patients in whom no mutation was identified.
Interestingly, 38 deaf individuals with homozygous c.919-
2A>G mutations underwent temporal bone computed-
tomography (CT) scans; all were confirmed to have EVA.
A definite etiologic diagnosis could be made using molecu-
lar diagnostics in individuals with concomitant hearing im-
pairment and biallelic SLC26A4 mutations. However, the
incidence of c.919-2A>G compound heterozygosity among
SNHL patients remains unknown. The number of cases
investigated to-date is limited and the contribution of
c.919-2A>G compound heterozygotes in the general deaf
population is unclear. In this study, we evaluated 80
patients with the SLC26A4 c.919-2A>G monoallelic muta-
tion from 1065 hearing-impaired subjects and reported
the occurrence of a second mutant allele in these patients.
Methods
Subjects
This study was performed according to a protocol
approved by the ethics committee of the Chinese PLA
General Hospital (equivalent to the Institutional ReviewBoard in Western nations). Informed consent was
obtained from parents of students <18 years old or from
adults >18 years old before blood sampling. Parents were
interviewed to obtain family history and maternal preg-
nancy history, in addition to the subject’s age at diagno-
sis and clinical history, including infections, possible
head or brain injuries, and exposure to aminoglycoside
antibiotics.
A retrospective review of 1065 patients with moderate-
to-profound bilateral sensorineural hearing loss at the
Chinese PLA General Hospital Genetic Testing Center for
Deafness revealed that the numbers of patients with
homozygous and heterozygous c.919-2A>G were 53
(5.0%) and 80 (7.5%) by polymerase chain-reaction (PCR)/
restriction-fragment-length polymorphism [14]. We eva-
luated the 80 patients with a c.919-2A>G single allelic mu-
tation and found no evidence of syndromic hearing
impairment. In these samples, no pathogenic mutation
had been identified by sequencing in GJB2.
A total of 82 unrelated Han subjects with normal hea-
ring sensitivity served as a control group. We used the
same screening method. The controls had no family his-
tory of hearing or speech disorders.
DNA isolation and sequencing
Mutation screening was performed by bidirectional se-
quencing on DNA extracted from whole blood and am-
plified by PCR.
Primer design and PCR amplification
Coding and flanking intron sequences of SLC26A4 exons
2 to 6 and 9 to 21 (GenBank accession number
NT_007933) were amplified by PCR using 17 primer
pairs (the common pairs of exons 11 and 12) [21]. PCR
reactions were performed in a 20-μL volume containing
100-ng DNA, 2 μM of each forward and reverse primer,
200 μM dNTPs, 1× PCR buffer (10 mM Tris–HCl, pH
8.3, 50 mM KCl, 2.5 mM MgCl2), and 1 U of DNA poly-
merase (Huamei, Beijing, China). PCR amplifications were
performed in a Gene Amp PCR System 9700 (Applied
Biosystems, Foster City, CA, USA) with an initial denatu-
ration step at 94°C for 1 min and then 34 cycles at 94°C
for 1 min, 60°C for 1 min, 72°C for 2 min, followed by 2
min of final extension at 72°C. The PCR products were
purified and sequenced using the BigDye Terminator
Cycle Sequencing kit (version v3.1) and ABI 3100 auto-
mated DNA sequencers (Applied Biosystems, Foster City,
CA, USA) with Sequence Analysis Software (Sequencing
Analysis version 3.7). DNA sequence variations were iden-
tified per reference sequences. The sequences were ana-
lyzed using the Genetool Lite software and the SLC26A4
GenBank sequence (ACCESSION: NT_007933, VER-
SION: NT_007933.14 GI: 51493052) (http://www.ncbi.
nlm.nih.gov/nuccore/51493052).
Table 1 Genotype and frequencies of 47 patients with
c.919-2A>G and second mutations in SLC26A4
Mutation Amino acids No. of alleles (% frequency)
c.279T>A* p.S93R 1 (1.25%)
c.281C>T p.T94I 1 (1.25%)
c.415+2T>C* Splice site 1 (1.25%)
(4+2T>C)
c.600+2T>A* Splice site 2 (2.5%)
(5+2T>A)
c.665G>T* p.G222V 1 (1.25%)
c.1079C>T p.A360V 1 (1.25%)
c.1174A>T p.N392Y 3 (3.75%)
c.1226G>A p.R409H 2(2.5%)
c.1229C>T p.T410M 4 (5%)
c.1545-2 A>G* Splice site 1 (1.25%)
(14-2A>G)
c.1548insC Frameshift 1 (1.25%)
c.1586T>G p.I529S 1 (1.25%)
c.1705+5G>A Splice site 4 (5%)
(15+5G>A)
c.1825delG* Frameshift 1 (1.25%)
c.1829C>A p.S610X 1 (1.25%)
c.1991C>T p.A664V 1 (1.25%)
c.2027T>A p.L676Q 4 (5%)
c. 2035-1G>A* Splice site 1 (1.25%)
(18-1G>A)
c.2168A>G p.H723R 16 (20%)
Alleles in bold italic type had frequencies >2%. *, novel mutation.
Li et al. Journal of Translational Medicine 2012, 10:225 Page 3 of 6
http://www.translational-medicine.com/content/10/1/225Statistical analysis
Pearson’s x2 test was used to evaluate the significance of
allelic associations. When the theoretical frequency was
<5, Fisher’s exact test was used. Pearson’s x2 test was
also used to compare differences in the frequencies of
mutations and exons. Statistical analyses were performed
using the Stata software, version 7.0 (Stata Corporation,
College Station, TX, USA).
Results
Our study sample consisted of 46 males and 34 females
aged 4–20 years (mean = 12.24 ± 4.76 years). SLC26A4
mutation screening was completed in all patients with a
single SLC26A4 c.919-2A>G mutation. A double-
heterozygous genotype was found in 47 of 80 patients
with a single c.919-2A>G mutation (58.8%), whereas 33
patients were heterozygous for c.919-2A>G without
other mutations.
Mutation data on the 80 Chinese subjects are shown
in Table 1. In one proband, an A to T substitution at
position 426 in exon 5 was found which not leading sub-
stitution of Proline at codon 142 in the third transmem-
brane domain of SLC26A4. The silent mutation and the
three intron variants (i.e., intron11+47T>C, intron2-
14C>T and intron18-13T>A) were not considered bialle-
lic SLC26A4 mutations.
A total of 19 mutations were identified, comprising
seven novel and 12 known mutations (Table 1). These
mutation sites were located in the coding region that
spanned 13 exons, except for exons 1, 2, 11, 12, 13, 16,
20, and 21, in which no mutations were identified. In
addition to exons 7+8, which contained c.919-2A>G,
three exons (exons 19, 10 and 17) and the flanking
sequences of exon 15 had more mutant alleles than
did others. The most common mutations, including
p.H723R, had a frequency of 20% (16 of 80). The next
most-common allele variants were p.T410M, 15+5G>A
(c.1705+5G>A) and p.L676Q (4 of 80, 5%). The differ-
ence between p.H723R and p.T410M was statistically
significant (p = 0.004). The fifth most-common mutation
was p.N392Y (3 of 80, 3.75%). The 14 remaining muta-
tions were detected only once or twice, with frequencies
of 1.25 and 2.5%. Our data suggest that these four exons
(exons 19, 10, 17 and 15) should be the priority for
SLC26A4 mutation screening.
We found ten types of missense mutations, five types
of splice-site mutations, two types of frameshift muta-
tions, and one type of nonsense mutation (Table 1). We
considered these SLC26A4 allele variants as potentially
pathologic in causing NSHL. We tested at least 82 con-
trols with normal hearing for all these mutations to de-
termine whether we should exclude mutations that were
common polymorphisms. None of the 19 mutations
were detected in 82 normal subjects.All the novel missense mutations occurred in the con-
served regions of the coded amino acid sequences, iden-
tified by the high sequence homologies among human,
mouse, and rat. Although translated protein can be
made in the presence of missense mutations for some
amino acid substitutions, missense mutations may result
in pendrin protein dysfunction.
Nine patients were compound heterozygous for splice
site mutations with c.919-2A>G. We considered these
mutations to be disease-causing factors. As the five
splice site mutations (i.e., 4+2T>C (c.415+2T>C),
5+2T>A (c.600+2T>A), 14–2 A>G (c. 1545–2 A>G),
15+5G>A (c.1705+5G>A)and 18–1 G>A (c. 2035-1G>A))
changed a conserved nucleotide in the splice-site consen-
sus sequence, these mutations likely affect SLC26A4
gene splicing. The c.1825delG mutation led to a pre-
dicted frameshift at position 608 of the pendrin protein
stop codon at position 634. Nonsense mutation of the
c.1829C>A substitution was found in exon 17, leading to
p.S610X. The frameshift mutation, c.1548insC, was iden-
tified by Park et al. in 2005 [16].
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We found intron11+47T>C variation had a higher carrier
frequency, with a frequency 14.6% (Homo5 and Hete7). A
variation intron 19-25T>A was identified three times
(Homo1 and Hete2). The c.919-2A>G heterozygous muta-
tion was detected once in 82 normal subjects. Eight varia-
tions [i.e., c.147C>G Hete (S49R), intron 2-32A>T Hete,
c.340G>A Hete (p.G114R), intron 7-18T>G Hete,
c.1927G>T Hete (E643X), c.1975G>C Hete (V659L), in-
tron 17-26A>G Hete, and c.2283A>G Homo (p.T761T)]
were identified once. None of the 19 mutations was
detected in 82 normal subjects. Allelic frequencies were
significantly different between patients and control sub-
jects for all five mutations (p.H723R, p.T410M, 15+5G>A
(c.1705+5G>A), p.L676Q and p.N392Y; Fisher’s exact test,
p = 0.000, 0.006 and 0.023, respectively).
Discussion
The progress made in research on hereditary hearing
loss indicates the importance of molecular diagnosis
using the SLC26A4 gene in patients with hearing loss
[22]. The molecular diagnosis of hearing impairment
associated with the SLC26A4 gene is reliable because
deafness is caused by homozygous or compound hetero-
zygous SLC26A4 mutations [6,23]. Previous studies
[13,24,25]. suggested that SLC26A4 c.919-2A>G is the
most frequent mutation in Taiwan and mainland China,
and that less-frequent mutations of other exons may be
detected by direct DNA sequence analysis [26]. In the
present study, 58.8% of patients carrying a heterozygous
c.919-2A>G mutation (47/80) had a definite form of
SNHL caused by a SLC26A4 mutation. We also found
that compound heterozygosity accounted for nearly 60%
of patients with two mutated alleles, which highlights
the importance of screening for SLC26A4 mutations
other than c.919-2A>G.
In this study, 19 mutations were identified, seven of
which were novel. Of these mutations, 16 were found
only in the Asiatic deaf population, whereas three were
identified in both Asians and Caucasians. It seems that
the spectrum of SLC26A4 mutations in the Chinese
population is different from that of European popula-
tions. The most common allele variant was p.H723R,
situated within exon 19, which accounted for 34% of all
mutant alleles. P.H723R appeared to be highly correlated
with nonsyndromic recessive deafness with EVA among
Chinese populations [13]. Park et al. [27] reported that
the p.H273R mutation is prevalent; this allele exists in
the majority of SLC26A4 mutations in Korean and Japa-
nese populations. The second-most-frequent mutations
(i.e., p.T410M, 15+5G>A (c.1705+5G>A), and p.L676Q)
occur at exon 10, exon 15 flanking sequences, and exon
17, respectively. Exons 19, 10, 17 and 15 (flanking
sequences) have highly variable region(s) in whichmultiple mutations were detected. Therefore, this study
showed that mutations other than c.919-2A>G exist
mostly in four exons (i.e., exons 19, 10, 17 and 15). The
mutation frequency in SLC26A4 exons 19, 17, 10, and
15 was consistent with the results of previous studies
[13]. However, our study was performed on patients with
severe to profound hearing impairment or deafness
(general deaf population), whereas Wang investigated
patients with hearing impairment and EVA/MD [13].
The distribution of mutant SLC26A4 alleles revealed by
our study suggests that mutation screening of four exons
(i.e., exons 19, 10, 17 and 15) following c.919 A>G iden-
tification should be the priority for NSHL genetic test-
ing, especially in EVA/MD patients.
We found seven SLC26A4 mutations that have not been
described previously. These included two missense muta-
tions, four splice-site mutations, and one frameshift muta-
tion. The missense mutations were probably pathogenic,
based on both their presence in affected individuals and
their predicted biological consequences. That is, a change
in an amino acid that is located in a functional domain or
that is conserved in related genes or species is likely to be
pathogenic. The missense mutations p.S93R and p.G222V
are most likely to be pathogenic based on the changes in
evolutionarily conserved amino acids, Serine to Arginine
and Glycine to Valine, respectively. However, as the
SLC26A4 gene is expressed only in thyroid, kidney, and
brain [7,12,28], and since none of these tissues was available
from patients, we were unable to evaluate the effect of the
mutation at the mRNA level. The splice site mutation is
frequently found in compound heterozygotes with a c.919-
2A>G mutation [29]. The pathogenic potential of splice site
mutations is unknown since their effect on splicing has not
been determined. We presume that these splice site muta-
tions could cause exon deletion and affect SLC26A4 mRNA
integrity and pendrin function. The SLC26A4 frameshift
mutation (c.1825 delG) was a nonsense mutation, resulting
in an unstable mRNA or truncated protein.
A second mutant allele was not detected among 33
patients in our study. It is unlikely that a single
SLC26A4 mutant allele is sufficient to cause EVA, as
there are no published reports of vertical co-segregation
of EVA with a single SLC26A4 mutant allele or sporadic
cases associated with a single de novo SLC26A4 mutant
allele [30]. In a previous study, we performed single mu-
tation screening of deaf individuals from Chifeng and
Nantong Cities, and found one mutant allele mutation
in SLC26A4 was identified in 8.45%(24/284) [31].
It still remains unclear whether or why the heterozy-
gous c.919-2A>G mutation affects the inner ear. It can
be assumed that patients with a single c.919-2A>G mu-
tation are more likely to develop hearing loss and EVA
in the presence of additional genes or environmental fac-
tors. On the basis of current knowledge, we speculate
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production or activity of the inner ear proton pump or
that environmental factors affect pump function in some
patients. First, a subset of individuals with a monoallelic
SLC26A4 gene mutation might harbor a second uniden-
tified mutation in the promoter or intronic regions of
this gene. It has been demonstrated that Foxil-null mice
have both enlarged endolymphatic ducts/sacs and hea-
ring loss, and Foxil is a possible upstream regulator of
SLC26A4 [32]. Yang et al. described several EVA
patients with a heterozygous SLC26A4 mutation in com-
bination with a heterozygous hypo-functional variant of
FOXI1 or KCNJ10 [33,34]. Mutations in introns that
may activate cryptic splice sites might be present in
human populations. Second, since deafness is associated
with GJB2 and GJB3 [35], it should be noted that the
deafness associated with the SLC26A4 gene might be a
consequence of digenic inheritance. Last, environmental
or unknown factors may explain the phenotype of EVA
patients with a single heterozygous c.919-2A>G muta-
tion. Alternatively, SLC26A4 epigenetic modifications,
such as DNA methylation, might repress gene transcrip-
tion and account for the observed co-segregation of
deafness and SLC26A4 monoallelic mutations [36].
We propose a new algorithm for genetic screening in
association with SLC26A4 mutations, based on the fre-
quency of mutations in different exons. In SNHL
patients, the SLC26A4 gene should be examined by pre-
ferential exon screening. If results are inconclusive, then
we propose mutation screening in sequence, since the
four most frequent types of mutations account for the
majority mutant alleles (66%) in our experience (Table 1).
If no mutations are detected in exons 19, 10, 17 or 15,
then analysis of other SLC26A4 exons should be under-
taken. This algorithm should detect almost two thirds of
mutant alleles and is particularly useful for genetic
screening in hearing loss patients.
EVA is associated with characteristic clinical findings,
including fluctuating and sometimes progressive sen-
sorineural hearing loss. Hearing loss in some EVA
patients is mild to moderate. This study was limited by
the moderate-to-profound hearing loss requirement,
which decreased EVA patient enrollment. However, our
findings show that biallelic SLC26A4 mutations are a
common cause of moderate-to-profound hearing loss.
Our results underscore the importance of a genetic
screening program that is capable of detecting different
SLC26A4 mutations. The screening of SLC26A4 gene
mutations will assist us with genetic counseling, and
screening for SLC26A4 gene mutations in patients with
moderate or profound hearing loss should be routine.
Furthermore, our data provide information that will fos-
ter genetic approaches to early diagnosis in the Chinese
population.Conclusion
In summary, 58.8% of the SLC26A4 IVS7-2A>G muta-
tion patients examined had clear SLC26A4-induced
SNHL. Our evaluation of SLC26A4 mutations provides a
basis for improving the clinical diagnosis of deaf patients
that may also in future be used in prenatal genetic ana-
lysis. Because CT or magnetic-resonance imaging (MRI)
is often difficult to perform in newborns, genetic testing
allows clear diagnosis and effective early treatment, such
as hearing aids or cochlear implantation. SLC26A4 mu-
tation screening can dramatically improve the identifica-
tion of causality, associated genetic counseling, and, to
some extent, patient management. Moreover, this obser-
vation highlights some of the difficulties in making a de-
finitive genetic diagnosis for deafness and illustrates
some of the challenges that may be associated with mo-
lecular genetic testing. The causes of EVA in patients
with nondiagnostic SLC26A4 genotypes are largely un-
known. Identification of additional genes or factors
underlying EVA would facilitate a more precise diagnosis
and could provide mechanistic insight into the patho-
genesis of hearing loss in this enigmatic disorder.
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